| Dr Ebaa Mohammed Alawami, MD | |
|
248 Pleasant St Ste 2800, Concord, NH 03301-7529 | |
| (603) 415-6464 | |
| (603) 227-7576 |
| Full Name | Dr Ebaa Mohammed Alawami |
|---|---|
| Gender | Female |
| Speciality | Dermatology |
| Experience | 19 Years |
| Location | 248 Pleasant St Ste 2800, Concord, New Hampshire |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1477707164 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208600000X | Surgery | 237577 (Massachusetts) | Secondary |
| 207N00000X | Dermatology | 18299 (New Hampshire) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Catholic Medical Center | Manchester, NH | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Northeast Dermatology Associates Pc | 3072403799 | 76 |
News Archive
BAC BV, the leading provider of antibody-based affinity purification technology, has extended its collaboration with GE Healthcare with the addition of a new bioprocess affinity chromatography ligand to GE Healthcare's range of custom designed media. The latest addition to the range is an affinity resin for the purification of alpha-1 antitrypsin (AAT) from blood plasma, recombinant cell culture or transgenic sources. The new resin has been developed as part of GE Healthcare's Custom Designed Media (CDM) programme and provides a new solution for AAT purification in the biopharmaceutical industry.
Stanford University School of Medicine scientists have discovered a novel class of compounds that, in experiments in vitro, inhibit replication of the virus responsible for hepatitis C. If these compounds prove effective in infected humans as well, they may dramatically accelerate efforts to confront this virus's propensity to rapidly acquire drug resistance, while possibly skirting some of the troubling side effects common among therapies in current use and in late-stage development.
The Cochrane Collaboration and John Wiley & Sons, Inc., the publisher of The Cochrane Library and Wiley Health Learning activities, today announced that they have extended their partnership by launching a new health professional development resource called Cochrane Learning.
Aarthi Narayanan, Associate Professor, and Lance Liotta, Co-Director, Center for Applied Proteomics and Molecular Medicine, are conducting three studies to assess the therapeutic efficacy of candidate interventions for COVID-19 in mouse models.
› Verified 6 days ago
| Entity Name | Concord Hospital Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1194778571 PECOS PAC ID: 6103721790 Enrollment ID: O20040405000916 |
News Archive
BAC BV, the leading provider of antibody-based affinity purification technology, has extended its collaboration with GE Healthcare with the addition of a new bioprocess affinity chromatography ligand to GE Healthcare's range of custom designed media. The latest addition to the range is an affinity resin for the purification of alpha-1 antitrypsin (AAT) from blood plasma, recombinant cell culture or transgenic sources. The new resin has been developed as part of GE Healthcare's Custom Designed Media (CDM) programme and provides a new solution for AAT purification in the biopharmaceutical industry.
Stanford University School of Medicine scientists have discovered a novel class of compounds that, in experiments in vitro, inhibit replication of the virus responsible for hepatitis C. If these compounds prove effective in infected humans as well, they may dramatically accelerate efforts to confront this virus's propensity to rapidly acquire drug resistance, while possibly skirting some of the troubling side effects common among therapies in current use and in late-stage development.
The Cochrane Collaboration and John Wiley & Sons, Inc., the publisher of The Cochrane Library and Wiley Health Learning activities, today announced that they have extended their partnership by launching a new health professional development resource called Cochrane Learning.
Aarthi Narayanan, Associate Professor, and Lance Liotta, Co-Director, Center for Applied Proteomics and Molecular Medicine, are conducting three studies to assess the therapeutic efficacy of candidate interventions for COVID-19 in mouse models.
› Verified 6 days ago
| Entity Name | Northeast Dermatology Associates Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1508061839 PECOS PAC ID: 3072403799 Enrollment ID: O20060105000473 |
News Archive
BAC BV, the leading provider of antibody-based affinity purification technology, has extended its collaboration with GE Healthcare with the addition of a new bioprocess affinity chromatography ligand to GE Healthcare's range of custom designed media. The latest addition to the range is an affinity resin for the purification of alpha-1 antitrypsin (AAT) from blood plasma, recombinant cell culture or transgenic sources. The new resin has been developed as part of GE Healthcare's Custom Designed Media (CDM) programme and provides a new solution for AAT purification in the biopharmaceutical industry.
Stanford University School of Medicine scientists have discovered a novel class of compounds that, in experiments in vitro, inhibit replication of the virus responsible for hepatitis C. If these compounds prove effective in infected humans as well, they may dramatically accelerate efforts to confront this virus's propensity to rapidly acquire drug resistance, while possibly skirting some of the troubling side effects common among therapies in current use and in late-stage development.
The Cochrane Collaboration and John Wiley & Sons, Inc., the publisher of The Cochrane Library and Wiley Health Learning activities, today announced that they have extended their partnership by launching a new health professional development resource called Cochrane Learning.
Aarthi Narayanan, Associate Professor, and Lance Liotta, Co-Director, Center for Applied Proteomics and Molecular Medicine, are conducting three studies to assess the therapeutic efficacy of candidate interventions for COVID-19 in mouse models.
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Ebaa Mohammed Alawami, MD 248 Pleasant St Ste 2800, Concord, NH 03301-7529 Ph: (603) 415-6464 | Dr Ebaa Mohammed Alawami, MD 248 Pleasant St Ste 2800, Concord, NH 03301-7529 Ph: (603) 415-6464 |
News Archive
BAC BV, the leading provider of antibody-based affinity purification technology, has extended its collaboration with GE Healthcare with the addition of a new bioprocess affinity chromatography ligand to GE Healthcare's range of custom designed media. The latest addition to the range is an affinity resin for the purification of alpha-1 antitrypsin (AAT) from blood plasma, recombinant cell culture or transgenic sources. The new resin has been developed as part of GE Healthcare's Custom Designed Media (CDM) programme and provides a new solution for AAT purification in the biopharmaceutical industry.
Stanford University School of Medicine scientists have discovered a novel class of compounds that, in experiments in vitro, inhibit replication of the virus responsible for hepatitis C. If these compounds prove effective in infected humans as well, they may dramatically accelerate efforts to confront this virus's propensity to rapidly acquire drug resistance, while possibly skirting some of the troubling side effects common among therapies in current use and in late-stage development.
The Cochrane Collaboration and John Wiley & Sons, Inc., the publisher of The Cochrane Library and Wiley Health Learning activities, today announced that they have extended their partnership by launching a new health professional development resource called Cochrane Learning.
Aarthi Narayanan, Associate Professor, and Lance Liotta, Co-Director, Center for Applied Proteomics and Molecular Medicine, are conducting three studies to assess the therapeutic efficacy of candidate interventions for COVID-19 in mouse models.
› Verified 6 days ago
Nava Chana Greenfield, MD Dermatology Medicare: Accepting Medicare Assignments Practice Location: 253 Pleasant St, Concord, NH 03301 Phone: 603-226-6119 | |
Andrew Kim, MD Dermatology Medicare: Accepting Medicare Assignments Practice Location: 253 Pleasant St, Dartmouth Hitchcock - Dermatology, Concord, NH 03301 Phone: 603-226-6119 | |
Dr. Peter Jonathan Sands, MD Dermatology Medicare: Accepting Medicare Assignments Practice Location: 253 Pleasant St, Concord, NH 03301 Phone: 603-226-2200 | |
Stephen Mark Delgiudice, M.D. Dermatology Medicare: Not Enrolled in Medicare Practice Location: 253 Pleasant St, Concord, NH 03301 Phone: 603-226-2200 | |
Dr. Paul Dacy Espy, MD Dermatology Medicare: Medicare Enrolled Practice Location: 253 Pleasant St, Dartmouth Hitchcock - Dermatology, Concord, NH 03301 Phone: 603-229-5200 | |
Scott Howard Deckelbaum, DO Dermatology Medicare: Accepting Medicare Assignments Practice Location: 248 Pleasant St Ste 2800, Concord, NH 03301 Phone: 603-415-6464 Fax: 603-227-7576 | |
Alexandra E Charos, MD Dermatology Medicare: Accepting Medicare Assignments Practice Location: 248 Pleasant St Ste 2800, Concord, NH 03301 Phone: 603-415-6464 Fax: 603-227-7576 |